

September 30, 2024

Qyuns Therapeutics Co., Ltd.

Room 1310, Building 1
No. 907 Yaocheng Avenue
Taizhou, Jiangsu
PRC

Attention: The Board of Directors

Dear Sirs,

Qyuns Therapeutics Co., Ltd. (the “Company”)

CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE DEVELOPMENT AND POTENTIAL COMMERCIALIZATION PARTNERSHIP OF QX005N WITH ZHONGMEI HUADONG

We refer to the circular of the Company dated September 30, 2024 in connection with the captioned matter (the “**Circular**”). Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise stated.

We hereby give and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter of advice and references to our name in the form and context in which they respectively appear.

We further confirm that, as at the Latest Practicable Date:

- (a) we did not have any direct or indirect interest in any asset which had been acquired, or disposed of by, or leased to any member of the Group since December 31, 2023, being the date to which the latest audited financial statements of the Group were made up, or was proposed to be acquired, or disposed of by, or leased to any member of the Group; and
- (b) we were not beneficially interested in the shares of any member of the Group; and we did not have any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group.

We further consent to this letter to be made available by the Company for inspection on the Stock Exchange's website and the Company's website in the manner set out in the section headed "10. DOCUMENTS ON DISPLAY" under the Appendix I - Additional Information to the Circular.

Yours faithfully,

For and on behalf of
Opus Capital Limited

A handwritten signature in black ink, consisting of stylized initials 'AC'.

Name: Andrew Cheung
Title: Executive Director